HCW Biologics resolves Nasdaq compliance, closes $5M offering, earns $7M license fee from WY Biotech

HCW Biologics Inc.

Nasdaq confirms compliance with bid price and MVPHS rules; company believes full compliance for Capital Market listing.
Closed $5M follow-on offering (671,140 units at $7.45/unit) and reduced existing warrant exercise price to $7.45.
WY Biotech license fully binding; HCW Biologics earns $7M upfront fee recognized in Q2 2025.
Converted $6.6M secured notes into common stock, warrants, and Wugen shares; reduced debt and improved equity.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.